Chapter 9: Indications for the treatment of primary hyperparathyroidism.

Helena Mosbah, Samuel Frey, Delphine Vezzosi, Olivier Chabre, Laurent Brunaud, Gianluca Donatini

Journal: Annales d'endocrinologie 2025;86(1):101698

PMID: 39818285

Full Text on Elsevier Science View on PubMed

Abstract

The choice of therapeutic method for the management of primary hyperparathyroidism depends on the severity of the disease and its complications at the time of diagnosis, the specific situation of each patient and his/her natural history, and assessment of the risk/benefit ratio for each method (surgery, local destruction or drugs). This chapter summarizes the indications for the treatment of primary hyperparathyroidism, based on the international literature available as of December 31st, 2023.

Address: Institut du thorax, chirurgie cancérologique, digestive et endocrinienne, institut des maladies de l'appareil digestif, CNRS, Inserm, CHU de Nantes, Nantes université, 44000 Nantes, France.; Endocrinology, Diabetology and Nutrition Department, CHU de Poitiers, Inserm, ECEVE UMR 1123, université Paris-Cité, Paris, France.; General and Endocrine Surgery Department, Inserm U1313-IRMETIST, CHU de Poitiers, Poitiers, France.; Département de chirurgie viscérale, métabolique et cancérologique (CVMC), CHRU de Nancy, Inserm U1256 NGERE, université de Lorraine, Nancy, France.; Department of Endocrinology, CHU de Grenoble-Alpes, University of Grenoble-Alpes, Inserm-CEA-UGA UMR1292, 38043 Grenoble, France.; Endocrinology, Diabetology and Nutrition Department, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse, France. Electronic address: [email protected].

DOI: 10.1016/j.ando.2025.101698

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Hyperparathyroidism, Primary, Parathyroidectomy